I-Viscosupplement ye-Knee Osteoarthritis
I-Monovisc iyilisi enye i- viscosupplement esetyenziselwa ukuphatha amanxungu amadolo achaphazelekayo yi- osteoarthritis . Ingeniso ye- intra-articular , intsingiselo, ifakwe kwi-joint joint. I-Monovisc yaphuhliswa ngu-Anika Therapeutics, Inc. kwaye yafumana imvume yokuthengisa evela kwi-US FDA ngomhla kaFebruwari 25, 2014. I-Monovisc ithengiswa yiDePuy Synthes, iMedk Sports Medicine phantsi kwesivumelwano selayisensi kunye no-Anika.
I-hyaluronan (ushukela oluyinkimbinkimbi yentsapho ye-glycosaminoglycan) kwi-Monovisc iyisisindo esikhulu samathambo, i-ultra purity derivative ye-hyaluronan yemvelo evela kwimvelaphi engeyiyo yezilwanyana. I-hyaluronan ivela kwiiseli zebhaktheriya kwaye iyaqhagamshelana nesisombululo esisemthethweni. I-Monovisc ihambisa i-dose efana ne- Orthovisc , enye i-Anika Therapeutics viscosupplement-kodwa i-Orthovisc ilawulwa kwinqanaba leejoviso ezintathu kunesisipha esisodwa.
Iinkcazo
I-Monovisc iboniswa ukunyanga kwe- knee osteoarthritis kwizigulane eziye zahluleka ukunyanga, njengoko kungabikho unyango lwezonyango kunye neyeza ezingenayo i-narcotic pain (umzekelo, i- acetaminophen ). Impawu eziphambili ze-knee osteoarthritis ngumonakalo we- cartilage obangela intlungu eninzi kunye nenqanaba elincinci lokunyuka kwi-joint joint. Kwi-osteoarthritis, kukho ukungaqhelekanga kunye ne- synovial fluid ngokunjalo. I-Synovial fluid iyayibhalela ngokubambisana ngokuqhelekileyo, evumela ukunyakaza okungahambisani nentambo.
Iimfosupplements, ezifana ne-Monovisc kunye nabanye abaye bavunywa ngaphambili, babuyela i-viscous, i-lubricating properties kwi-joint.
Iziphumo zophando
Ukhuseleko kunye nokusebenza ngedatha kwi-kliniki engabonakaliyo, elawulwayo, ephindwe kabini engama-369 abathathi-nxaxheba be-knee osteoarthritis kumaziko angama-31 e-US naseKhanada yayisisiseko sokuvunyelwa kwe-FDA ye-Monovisc, ngokwe-Anika Therapeutics.
Abathathi-nxaxheba babekwa nge-random nge-Monovisc okanye i-injine injections (ulawulo). Bavavanywa ukuphucula intlungu edibeneyo usebenzisa i-WOMAC (i-Western Ontario ne-McMaster iYunivesithi ye-Osteoarthritis Index), ngokukodwa ukukhangela izigulane ze-Monovisc eziphumelele ekuphuculweni okukhulu kwinqanaba labo le-WOMAC xa kuthelekiswa nokulawula izigulane kwixesha leveki ezili-12. Icandelo lokhuseleko lohlalutyo luchaza "izinga eliphantsi kakhulu kwezityalo ezimbi" kwaye akukho ziganeko ezimbi ezimbi kunye ne-Monovisc.
Ezinye iiViscosupplements
I-viscosupplement yokuqala yavunywa ngo-1997. Kukho ezinye i-viscosupplements ezi-5, ezininzi zazo zifuna uluhlu lweejovane kunokuba zifumane enye injini.
- Hyalgan
- I-Synvisc kunye ne-Synvisc-One (injini enye eyenziwe kwimikoko yenkukhu)
- Supartz
- IOrthovisc
- Euflexxa
Ukusebenza kweViscosupplementation
Ngo-2012, ingxelo epapashwe kwi- Annals ye-Internal Medicine yagqiba ukuba i-viscosupplementation yayingasebenzi kwaye ingozi. Ingxelo yathi i-viscosupplementation ivelisa ukunciphisa ukungabalulekanga kwintlungu xa kusenokunyusa umngcipheko wokuhlaselwa kunye neziganeko ezimbi. Esi sigqibo sisekwe kuhlalutyo lwe-meta lwama-89 alinganisekanga alingo olubandakanya izigulane ezingama-12,000 ze-knee osteoarthritis.
Nangona kunjalo, i-American Academy ye-Orthopedic Surgeons ithi "i-Viscosupplementation inokunceda abantu abane-arthritis abangazange bayiphendule kwiindlela zokwelapha ezisisiseko. kwi-site injection, kwaye ngamanye ama-injection kubangelwa ukukhukhuma okukhulu. Kungathabatha iiveki ezimbalwa ukuphawula ukuphucula emva kokuvela kwe-viscosupplementation .Iziko zonke izigulane ziya kuba neentlungu zentlungu. ngokuqhelekileyo iinyanga ezili-6. Ukusebenza kwexesha elide lwe-viscosupplementation akukaziwa kwaye uphando luqhubeka kule ndawo. "
> Imithombo:
> I-FDA ivumela i-Monovisc, Ulwaphulo olutsha oluNyango oluNyango lweNyango yoBula ngenxa ye-Osteoarthritis ye-Knee. Anika Therapeutics. NgoFebruwari 25, 2014.
I-Osteoarthritis ye-Knee: Uhlolo lokuHlola kunye nokuhlaziywa kweMeta. Agasti 7, 2012. Rutjes et al. Amanqaku angamayeza angaphakathi.
> I-Viscosupplementation Treatment for Arthritis. OrthoInfo. AAOS. Epreli 2013.